Nanalysis Provides Business Update Highlighting Quantum Technology Partnerships, $1Million in Non-Dilutive Non-Repayable Funding Award, Contract Wins and Corporate Activities

Rhea-AI Summary

Nanalysis Scientific (OTCQX:NSCIF) announced multiple updates, including quantum and MRI technology partnerships, government funding, capital raises and leadership changes.

Key items include a collaboration with NVision Quantum Technologies, expanded work with IMRIS, a $1 million non‑repayable PrairiesCan contribution, a $132,500 insider-led private placement, stock option grants, and the permanent appointment of Heather Kury as CFO.

AI-generated analysis. Not financial advice.

Positive

• $1 million non-repayable PrairiesCan contribution to support supply chain and export growth
• NVision orders six NMR spectrometers, supporting POLARIS commercialization efforts
• Expanded IMRIS partnership for magnetic resonance electronics, software and consulting
• $132,500 non-brokered private placement completed at $0.15 per unit
• 501,000 stock options granted at $0.15, aligning management incentives
• Appointment of experienced finance executive Heather Kury as permanent CFO

Negative

• Private placement units and warrants increase potential share count and dilution
• 501,000 stock options at $0.15 add to future equity dilution
• Private placement remains subject to final TSX Venture Exchange acceptance
• Insider participation triggers related-party transaction considerations under MI 61-101

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CALGARY, AB, June 23, 2026 Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, FRA: 1N1), a leader in portable NMR spectrometers and imaging technology for industrial and research applications, announces a series of strategic developments, including a quantum technology partnership with NVision Quantum Technologies GmbH ("NVision"), an expanded collaboration with IMRIS, government funding support, contract wins within its service division, and various corporate initiatives.

"These developments demonstrate the increasing relevance of Nanalysis' technology and expertise across several high-growth markets," said Sean Krakiwsky, Founder and CEO of Nanalysis. "From enabling next-generation quantum sensing applications and advancing interoperable MRI innovation, to securing new service contracts and strengthening our balance sheet, we continue to execute on our strategy of building a diversified technology company with multiple growth drivers."

Collaboration with NVision Quantum Technologies GmbH ("NVision")

NVision is a Germany-based quantum technology company focused on healthcare, with deep expertise in engineering and controlling the quantum properties of organic molecules. Its work spans two platforms: PIQC, a molecular quantum computing architecture that combines long-lived spin qubits with native photonic interfaces to support scalable quantum computing, and POLARIS, a quantum-enhanced MRI platform designed to make metabolic imaging accessible on standard MRI systems. Through these technologies, NVision aims to support more effective drug development, earlier disease assessment, and better-informed clinical decision-making.

Nanalysis supports NVision's commercialization efforts by providing a robust and user-friendly quality control solution for its POLARIS platform. Our technology enables reliable performance verification during both system installation and maintenance, helping ensure consistent performance, streamlined deployment, and operational confidence as NVision expands its installed base. As POLARIS moves toward broader market adoption, Nanalysis' solutions play an important role in supporting scalability and maintaining high-quality standards across deployments. As part of this collaboration, NVision has just placed an order for six Nanalysis NMR spectrometers, which highlights the company's expanding operations, growing confidence in Nanalysis technology, and the strong potential for continued investment as its imaging platform advances toward broader commercialization.

Regional Tariff Response Initiative funding

Prairies Economic Development Canada (PrairiesCan) has awarded Nanalysis a $1 million non-repayable contribution to support initiatives aimed at strengthening the Company's supply chain resiliency, expanding international market opportunities, and enhancing its competitiveness in strategic export markets. PrairiesCan is the federal department that leads in building a strong, competitive Canadian economy by supporting business growth, innovation and community economic development across Alberta, Saskatchewan and Manitoba.

"In an increasingly uncertain world, the Government of Canada is focused on what we can control: building a stronger, more resilient economy here at home. Central to that effort is investing in Alberta businesses that drive innovation and create good jobs," said the Honourable Eleanor Olszewski, Minister of Emergency Management and Community Resilience and Minister responsible for Prairies Economic Development Canada (PrairiesCan). "By investing in Calgary-based Nanalysis, we are strengthening our supply chains, supporting growth in global markets, and reinforcing Alberta's leadership in advanced technology—helping to build a more competitive economy while creating new opportunities for workers here at home."

"Alberta is playing an increasingly important role in Canada's health, energy, environmental, and food sectors, and Calgary-based Nanalysis demonstrates the talent, expertise, and drive to scale-up innovative solutions, "said Corey Hogan, Member of Parliament for Calgary Confederation and Parliamentary Secretary to the Minister of Energy and Natural Resources. "Today's investment through the Regional Tariff Response Initiative will help this innovative company strengthen its resilience by diversifying supply chains and expanding their market reach."

Partnership with IMRIS Imaging, Inc. ("IMRIS")

IMRIS is a US-based, private-equity backed provider of innovative intraoperative MRI systems specifically for imaging during neurosurgical procedures. In Q3 2025, IMRIS selected Nanalysis as a critical component supplier. Recently, the two companies have expanded this partnership to include other magnetic resonance market opportunities, for which Nanalysis can provide its magnetic resonance electronics and software modules as part of IMRIS' high-filed NMR solutions, based on its cryogen-free superconducting magnet technology for high resolution liquid state spectroscopy. Through its European subsidiary, RS2D, Nanalysis is also providing system architecture, consulting expertise, to support the development of IMRIS' next-generation technologies. These projects further expand Nanalysis' contributions to advanced medical imaging and magnetic resonance technologies, while showcasing the breadth of the Company's technical capabilities across the MRI and NMR ecosystem.

Private Placement of $132,500 Completed by Newly Appointed Directors

Nanalysis is pleased to announce the completion of a non-brokered private placement (the "Offering") of 883,333 units of the Company (the "Units") at a price of $0.15 per Unit for gross proceeds of approximately $132,500. The offering was completed by two recently appointed directors of the Company, Jonathan Ladd and Werner Maas, demonstrating their confidence in Nanalysis and alignment with shareholders. The net proceeds of the Offering will be used by the Company for general corporate purposes

Each Unit consists of one common share of the Company (a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder to acquire one additional Share at an exercise price of $0.20 per Share at any time up to 4:00 p.m. (Calgary time) on or before the date that is two years from the applicable closing date.

No finder's fee or commission was paid in connection with the Offering. The Offering remains subject to final acceptance of the TSX Venture Exchange. All securities issued under the Offering are subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities laws.

The participation of Jonathan Ladd and Werner Maas, as insiders of the Company, constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements under sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, on the basis that the fair market value of the insider's participation does not exceed 25% of the Company's market capitalization.

Stock Options issued to three new Board Members and Employees

The Company's Board of Directors has granted 501,000 stock options ("Options") to certain directors of the Company.

All stock options have been issued pursuant to the Company's stock option plan: Each Option is exercisable, once vested, to purchase one common share of the Company at $0.15 per share for a period of five years from the date of issuance.

Appointment of Heather Kury to CFO

The Company is pleased to announce the appointment of Heather Kury, CPA, CA, as Chief Financial Officer following her service as interim CFO Ms Kury has more than twenty years of experience helping both public and private companies improve corporate strategy and operational performance. Prior to joining Nanalysis, she held senior finance and leadership roles in the oil and gas and information technology sectors Ms Kury is a member of the Institute of Chartered Professional Accountants of Alberta and holds a Bachelor of Arts from the University of Winnipeg.

Sean Krakiwsky, Founder and CEO of Nanalysis, commented: "Heather has already made significant contributions to Nanalysis during her time as Interim CFO, and we are pleased to welcome her to the role on a permanent basis. Her financial leadership and operational experience will be valuable as we continue executing our growth strategy."

About Nanalysis Scientific Corp. (TSXV: NSCI, FRA:1N1)

Nanalysis Scientific Corp. develops and manufactures benchtop Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-provides-business-update-highlighting-quantum-technology-partnerships-1million-in-non-dilutive-non-repayable-funding-award-contract-wins-and-corporate-activities-302807496.html

SOURCE Nanalysis Scientific Corp.

FAQ

What quantum technology partnership did Nanalysis (NSCIF) announce with NVision on June 23, 2026?

Nanalysis announced support for NVision’s POLARIS quantum-enhanced MRI platform, supplying NMR spectrometers and quality control solutions. According to Nanalysis, NVision has placed an order for six instruments to aid installation, maintenance, and performance verification as POLARIS moves toward broader commercialization.

How much non-dilutive funding did Nanalysis (NSCIF) receive from PrairiesCan in June 2026?

Nanalysis received a $1 million non-repayable contribution from PrairiesCan. According to Nanalysis, the Regional Tariff Response Initiative funding will strengthen supply chain resiliency, expand international market opportunities, and enhance competitiveness in strategic export markets across health, energy, environmental and food-related applications.

What is the significance of Nanalysis (NSCIF) expanding its partnership with IMRIS Imaging?

Nanalysis expanded its role as a component supplier for IMRIS intraoperative MRI systems and other magnetic resonance markets. According to Nanalysis, it will provide electronics, software modules and RS2D consulting expertise, supporting IMRIS’ cryogen-free superconducting magnet technology and next-generation high-field spectroscopy solutions.

What are the details of the June 2026 Nanalysis (NSCIF) private placement by new directors?

Nanalysis completed a non-brokered private placement of 883,333 units at $0.15, raising about $132,500. According to Nanalysis, each unit includes one share and half a warrant exercisable at $0.20 for two years, with participation by directors Jonathan Ladd and Werner Maas.

How will the June 2026 stock option grants affect Nanalysis (NSCIF) share structure?

Nanalysis granted 501,000 stock options to certain directors under its stock option plan. According to Nanalysis, each option allows the purchase of one common share at $0.15 for five years, adding potential future dilution but aligning long-term incentives with shareholder interests.

Who is the new Chief Financial Officer of Nanalysis (NSCIF) appointed in June 2026?

Nanalysis appointed Heather Kury, CPA, CA, as permanent Chief Financial Officer after serving as interim CFO. According to Nanalysis, she brings over twenty years of finance and operational experience from public and private companies in oil and gas and information technology sectors.

Does the June 2026 Nanalysis (NSCIF) insider private placement raise related-party concerns?

The offering involved insiders Jonathan Ladd and Werner Maas, making it a related-party transaction under MI 61-101. According to Nanalysis, it relied on exemptions from formal valuation and minority approval because insider participation did not exceed 25% of market capitalization.